Election Day SALE: 60% Off VIP Membership
The Liberal Media Is Seething Right Now Heading Into Election Day
We Could Witness the Greatest Political Comeback of All Time Tonight
Detroit Polling Location Threatened
Election Day Is Not the Finish Line
Calling Trump 'Hitler' Has Done Permanent Damage to the Moral Realm
Trump Has Reason in Pennsylvania to Feel Better Than Harris
Is It Too Early to Talk 2028?
Thank God for the Electoral College
Do the Unrighteous Now Outnumber the Righteous in America?
Voter Turnout and Ballot Completion Is Everything
The Elites Are About to Hand Trump a Second Term
Kamala Harris’ Energy Policies Are More Extreme and Harmful Than Biden’s
Abortion: America’s Worst Vice
Trump’s ‘Operation Aurora’ Is Essential to Stop the Tren de Aragua From Taking...
Tipsheet

The First Wuhan Coronavirus Vaccine Has Promising Results

AP Photo/Ted S. Warren, File

The first Wuhan coronavirus vaccine is showing promising results, meaning it's likely to begin a final clinical trial. Researchers say the vaccine boosted people's immune systems, which could be enough to protect against the virus.

Advertisement

The initial trial began in March with 45 young volunteers. Those original volunteers had neutralizing antibodies in their bloodstream, which are key to blocking infections. The research team told the New England Journal of Medicine the antibodies are similar to those who were infected and survived the virus.

“No matter how you slice this, this is good news,” Dr. Anthony Fauci, the head of the National Institute of Allergies and Infectious Diseases (NIAID) told the Associated Press.

The vaccine was developed by the National Institutes of Health and Moderna Inc., which has researchers from the NIAID working on the project.

Because of the positive results the original volunteers had, the next stage would mean testing the vaccine on 30,000 people. That will give researchers an idea of how effective the vaccine would be to protect the American public against the Wuhan coronavirus.

In the next phase, older adults and those with pre-existing conditions will be included. There will also be an emphasis on testing the vaccine on blacks and Latinos, which have also been heavily ravaged by the virus.

Advertisement

“This is an essential building block that is needed to move forward with the trials that could actually determine whether the vaccine does protect against infection,” the study's leader, Dr. Lisa Jackson of the Kaiser Permanente Washington Research Institute in Seattle, told the AP.

The vaccine comes in two doses, one month apart. No serious side effects have been reported. The majority of volunteers had typical flu-like reactions, which are common with other vaccines, including fatigue, headache, chills, fever and pain at the injection site. 

Those who wish to sign up to be part of the trail are encouraged to do so.

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement